These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1234 related articles for article (PubMed ID: 21549516)

  • 21. Image guided volumetric response during chemoradiotherapy for head and neck squamous cell carcinoma as a predictor of disease outcomes.
    Davuluri R; Krase JM; Cui H; Goyal UD; Cheung MK; Hsu CC; Yi SK
    Am J Otolaryngol; 2016; 37(4):304-10. PubMed ID: 27105977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522.
    Schwartz DL; Harris J; Yao M; Rosenthal DI; Opanowski A; Levering A; Ang KK; Trotti AM; Garden AS; Jones CU; Harari P; Foote R; Holland J; Zhang Q; Le QT
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):721-9. PubMed ID: 25752384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
    Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-category remains an important prognostic factor for oropharyngeal carcinoma in the era of human papillomavirus.
    Mackenzie P; Pryor D; Burmeister E; Foote M; Panizza B; Burmeister B; Porceddu S
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):643-7. PubMed ID: 25001635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy.
    Lim SH; Lee SJ; Ahn MJ; Park K; Sun JM
    Jpn J Clin Oncol; 2016 Jan; 46(1):40-5. PubMed ID: 26561556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective analysis of the clinical efficacy of definitive chemoradiotherapy for patients with hypopharyngeal cancer.
    Takehana K; Kodaira T; Tachibana H; Kimura K; Shimizu A; Makita C; Tomita N; Nishikawa D; Suzuki H; Hirakawa H; Hanai N; Hasegawa Y
    Jpn J Clin Oncol; 2016 Apr; 46(4):344-9. PubMed ID: 26826721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.
    Yom SS; Machtay M; Biel MA; Sinard RJ; El-Naggar AK; Weber RS; Rosenthal DI
    Am J Clin Oncol; 2005 Aug; 28(4):385-92. PubMed ID: 16062081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary surgery for advanced-stage laryngeal cancer: A stage and subsite-specific survival analysis.
    Harris BN; Bhuskute AA; Rao S; Farwell DG; Bewley AF
    Head Neck; 2016 Sep; 38(9):1380-6. PubMed ID: 27014858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Earlier and more specific detection of persistent neck disease with diffusion-weighted MRI versus subsequent PET/CT after definitive chemoradiation for oropharyngeal squamous cell carcinoma.
    Yu Y; Mabray M; Silveira W; Shen PY; Ryan WR; Uzelac A; Yom SS
    Head Neck; 2017 Mar; 39(3):432-438. PubMed ID: 27726241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of Recurrence in Electively Irradiated Lymph Node Regions After Definitive Accelerated Intensity Modulated Radiation Therapy for Head and Neck Squamous Cell Carcinoma.
    van den Bosch S; Dijkema T; Verhoef LC; Zwijnenburg EM; Janssens GO; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):766-74. PubMed ID: 26972649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Rades D; Seibold ND; Gebhard MP; Noack F; Schild SE; Thorns C
    Strahlenther Onkol; 2011 Oct; 187(10):626-32. PubMed ID: 21932027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDG-PET prediction of head and neck squamous cell cancer outcomes.
    Schwartz DL; Rajendran J; Yueh B; Coltrera MD; Leblanc M; Eary J; Krohn K
    Arch Otolaryngol Head Neck Surg; 2004 Dec; 130(12):1361-7. PubMed ID: 15611393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and
    Ng SH; Liao CT; Lin CY; Chan SC; Lin YC; Yen TC; Chang JT; Ko SF; Fan KH; Wang HM; Yang LY; Wang JJ
    Eur Radiol; 2016 Nov; 26(11):4162-4172. PubMed ID: 26911889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for local-regional recurrence following preoperative radiation therapy and surgery for head and neck cancer (stage II-IVB).
    Shikama N; Sasaki S; Nishikawa A; Koiwai K; Yoshino F; Hirase Y; Kawakami R; Kadoya M; Oguchi M
    Radiology; 2003 Sep; 228(3):789-94. PubMed ID: 12954897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of hypoxia-associated markers in advanced larynx and hypopharynx squamous cell carcinoma.
    Bernstein JM; Andrews TD; Slevin NJ; West CM; Homer JJ
    Laryngoscope; 2015 Jan; 125(1):E8-15. PubMed ID: 25230150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer.
    Rosenthal DI; Mohamed ASR; Garden AS; Morrison WH; El-Naggar AK; Kamal M; Weber RS; Fuller CD; Peters LJ
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1002-1011. PubMed ID: 28721881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retropharyngeal adenopathy as a predictor of outcome in squamous cell carcinoma of the head and neck.
    McLaughlin MP; Mendenhall WM; Mancuso AA; Parsons JT; McCarty PJ; Cassisi NJ; Stringer SP; Tart RP; Mukherji SK; Million RR
    Head Neck; 1995; 17(3):190-8. PubMed ID: 7782203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
    Chang CL; Yuan KS; Wu SY
    Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group.
    Yoo GH; Moon J; Leblanc M; Lonardo F; Urba S; Kim H; Hanna E; Tsue T; Valentino J; Ensley J; Wolf G
    Arch Otolaryngol Head Neck Surg; 2009 Sep; 135(9):869-74. PubMed ID: 19770418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of daily fraction size on laryngoesophageal dysfunction after chemoradiation for squamous cell carcinomas of the larynx and hypopharynx.
    Chen AM; Hsu S; Meshman J; Chin R; Beron P; Abemayor E; St John M
    Head Neck; 2017 Jul; 39(7):1322-1326. PubMed ID: 28301066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.